Arcutis Biotherapeutics, INC 8-K filings

Arcutis Biotherapeutics announced the appointment of experienced biopharmaceutical executive Christopher Peetz to its Board of Directors, effective July 15, 2026.

Arcutis Biotherapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all three proposals, including director elections and auditor ratification, were approved.

Arcutis Biotherapeutics announced first-quarter 2026 financial results, with net product revenue reaching $105.4 million, driven by strong demand for ZORYVE.

Arcutis Biotherapeutics reported strong Q4 and full-year 2025 financial results, driven by ZORYVE sales growth, positive clinical data, and increased 2026 revenue guidance.

Arcutis Biotherapeutics strengthens its Board with the appointment of Amit Munshi as a Class II director and Compensation Committee chair, following the retirement of founder Bhaskar Chaudhuri.

Arcutis Biotherapeutics announced robust third-quarter 2025 financial results, driven by a 122% surge in ZORYVE net product revenue and new FDA approval for pediatric atopic dermatitis.

Arcutis Biotherapeutics reports strong second-quarter 2025 financial results with significant revenue growth and reduced net loss, driven by robust ZORYVE product demand and new FDA approval.

Arcutis Biotherapeutics, Inc. announced that its stockholders approved all three proposals at the 2025 Annual Meeting, including the election of directors and the ratification of its auditor, while the Board also approved revisions to its non-employee director compensation program.

Arcutis Biotherapeutics announced a 196% increase in ZORYVE net product revenue for Q1 2025 compared to Q1 2024, reaching $63.8 million.

Arcutis Biotherapeutics announces the appointment of Latha Vairavan as the new CFO, succeeding David Topper who will retire after a period of transition.

Arcutis Biotherapeutics reports a significant increase in revenue for Q4 and full year 2024, driven by strong demand for ZORYVE and strategic commercial initiatives.

Arcutis Biotherapeutics reports preliminary unaudited product revenue of approximately $63 million for Q4 2024 and $160 million for the full year, marking significant growth.

Arcutis Biotherapeutics announced a 45% sequential revenue growth in Q3 2024, driven by strong demand for its ZORYVE product line and improvements in gross-to-net pricing.

Arcutis Biotherapeutics announced a significant 547% year-over-year increase in ZORYVE franchise revenue for Q2 2024, alongside key strategic advancements.

Arcutis Biotherapeutics successfully held its 2024 Annual Meeting of Stockholders, approving the election of directors, ratification of the auditor, and executive compensation.

Arcutis Biotherapeutics announced a significant increase in first-quarter revenue, driven by strong sales of its ZORYVE products and a strategic licensing agreement.

Arcutis Biotherapeutics has appointed David Topper as its new Chief Financial Officer, effective April 10, 2024, succeeding interim CFO John Smither.

Arcutis Biotherapeutics successfully completed a public offering of common stock, raising approximately $161.6 million to fund its commercialization and development programs.

Arcutis Biotherapeutics has granted Sato Pharmaceutical exclusive rights to develop and commercialize ZORYVE cream and foam in Japan, securing an upfront payment and potential future royalties.

Arcutis Biotherapeutics announced a significant increase in fourth-quarter revenue driven by ZORYVE product sales and provided updates on its pipeline and recent corporate activities.

Arcutis Biotherapeutics successfully concluded its stock option exchange program, resulting in the cancellation of over 5 million stock options and the issuance of approximately 2.1 million new restricted stock units.

Arcutis Biotherapeutics is offering a voluntary, one-time option exchange program allowing eligible employees and consultants to exchange certain stock options for a lesser number of restricted stock units.